Navigation Links
For Pharma Companies, Launching Multiple Similar Products Can Be a "Good Problem" but Requires Smart Resourcing
Date:5/3/2013

CHAPEL HILL, N.C., May 3, 2013 /PRNewswire/ -- In a healthcare market where even the largest pharma manufacturers must squeeze revenue from every product in the portfolio, some companies are confronted with the "good problem" of having a rich pipeline featuring multiple new products. 

But launching and promoting each new product is both costly (hiring and training new "people resources" such as field sales reps) and strategically challenging (effectively positioning similar products).  To succeed in this critical task, healthcare commercial leaders and brand managers have in many cases begun to embrace a franchise approach to promoting similar products.

According to new research from Best Practices, LLC, a franchise approach is paying tangible dividends for many companies, enabling franchise users to cut overall promotional costs, boost efficiencies across product support teams, and accrue the reputational benefits of being seen as a treatment leader in a given therapeutic area.

For example, our latest research reveals that:

  • The highest net franchise cost savings come in reducing average sales force size & training (58% of franchises), increasing sales force effectiveness (57%), and enhanced customer targeting (57%).
  • 74% of franchises effectively removed redundancies in customer targeting, enabling greater rep effectiveness during key lifecycle stages – keeping territories smaller and shrinking rep-to-customer ratios during launch.
  • From a risk perspective, the chances for launch failure within a franchise expand exponentially when multiple launches occur within a short window (i.e., less than 6 months).  Poor rep execution in messaging and product differentiation is the greatest liability in rapid multiple launches.

To help equip healthcare Sales, Marketing, and Commercial leaders with the tools and insights needed to effectively and efficiently launch and promote multiple products, Best Practices, LLC conducted this critical research, which is now available in the new primary research report "Best Practices in Launch Optimization: How Promotional Efficiency can be Leveraged to Support Multiple Products & Indications".  

Key study topics examined include:

  • Managing Similar Products or an Integrated Product Portfolio
  • Optimizing Sales Resources within Franchise Operations
  • Combining Resources for Efficiently Marketing Multiple Products with Similar Indication
  • Optimal Brand Team Approaches for Product Franchise

To learn more about this report, download a complimentary report excerpt by clicking here. For more information on other recent primary research studies, contact us at 919.403.0251, or visit our website at bestpractices@best-in-class.com. Check out our new blog at http://whybenchmarking.com/ for more benchmark studies.

ABOUT BEST PRACTICES, LLC
Best Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide.  Our clients include 48 of the top 50 leading global healthcare companies. We conduct primary research and consulting using comprehensive proprietary benchmarking tools and analysis. The operational insights, findings and analysis form the basis of our Benchmarking Reports, databases and advisory services to support executives in commercial and R&D operations.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. AcelRx Pharmaceuticals to Hold First Quarter 2013 Financial Results Conference Call and Webcast on May 8, 2013
2. Valeant Pharmaceuticals Provides Efinconazole Update
3. Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2013 Financial Results
4. Cumberland Pharmaceuticals Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013
6. Webcast Alert: Isis Pharmaceuticals First Quarter 2013 Financial Results Conference Call
7. 2013 Pharmaceutical Drug Naming Trends
8. SynteractHCR Addressing Successful Ways to Approach Sponsor and CRO Collaboration at May Pharmaceutical Events in US and Europe
9. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2013 Financial Results
10. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes
11. Frost & Sullivan: Pharma and Biotech Industries Headed Toward an Era of Reduced Profit Margins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... SEATTLE , Feb. 27, 2017  CTI BioPharma Corp. ... of Adam Craig , M.D., Ph.D., as President and ... Directors effective March 20, 2017. Dr. Craig succeeds Richard ... serve on the company,s Board of Directors.  Dr. Craig has ... development in both the US and Europe ...
(Date:2/27/2017)... -- Period October – December 2016 Revenues ... SEK -16.4 (-6.4) million Result after tax amounted to SEK ... dilution Cash flow from operating activities amounted to SEK -8.3 ... Period full year ... Operating result amounted to SEK -39.5 (-29.5) million ...
(Date:2/24/2017)... , Feb. 24, 2017  Today, exocad America ... labs have a new path to produce 510(K) ... Biodenta implant library integrated into exocad DentalCAD software. ... FDA compliant Good Manufacturing Processes (GMP,s) into their ... Biodenta, and complete an audit process. Then, dental labs ...
Breaking Medicine Technology:
(Date:2/27/2017)... RICHEY, Fla. (PRWEB) , ... February 27, 2017 , ... ... disorder, but concern for women who become dependent on opioid painkillers has fallen short. ... female patients, compared to a 237% increase in fatal overdoses in male populations.(1) , ...
(Date:2/27/2017)... , ... February 27, 2017 , ... Orange County ... a chronic inflammatory gum condition that occurs when the bacteria in plaque infect the ... referred to as a scaling and root planing or SRP, and can include surgical ...
(Date:2/27/2017)... ... February 27, 2017 , ... POUGHKEEPSIE, N. Y. – ... disclosed that despite scientific studies, the Center for Disease Control ( CDC ) and ... . Kenneth B. Liegner, M.D. has compiled into a single volume a compelling ...
(Date:2/27/2017)... ... February 27, 2017 , ... Silicon Valley Hair ... announce a new informational post on robotic hair transplantation. San Francisco residents may ... transplant and Follicular Unit Transplantation (FUT) can sound similar. Either treatment can be ...
(Date:2/26/2017)... ... February 25, 2017 , ... The February 13, 2017, assassination of ... concern over nerve agents and the deadly use of chemical weapons. Many questions exist ... how even small doses can be lethal. , Jay Jagannathan, M.D., of Michigan-based Jagannathan ...
Breaking Medicine News(10 mins):